Den Europæiske Union - dansk - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae stamme ms-h - immunologicals for aves, live bakterielle vacciner - kylling - til aktiv immunisering af fremtidige slagtekyllinger, kyllinger fra fremtidige lagdeltagere og fremtidige lagkyllinger for at reducere lungerne og reducere antallet af æg med unormal skaldannelse forårsaget af mycoplasma synoviae.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

elanco gmbh - mycoplasma hyopneumoniae, stamme p-5722-3 (inaktiveret) - injektionsvæske, emulsion - 6000 ru/dosis - svin

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svin - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

intervet international b.v. - porcint circovirus type 2 (pcv2) orf2 subunit-antigen, mycoplasma hyopneumoniae j stamme inaktiverede - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svin (slagtekyllinger) - til aktiv immunisering af svin for at reducere viraemia, virus belastning i lungerne og lymfoide væv, virus kaste forårsaget af porcint circovirus type 2 (pcv2) infektion, og sværhedsgraden af lunge læsioner forårsaget af mycoplasma hyopneumoniae infektion. for at reducere tabet af daglig vægtforøgelse i efterbehandlingstiden i lyset af infektioner med mycoplasma hyopneumoniae og / eller pcv2 (som observeret i feltundersøgelser).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inaktiveret virus og bakterier inaktiverede vacciner - svin - til aktiv immunisering af svin fra 3 ugers alderen mod porcine circovirus type 2 (pcv2) for at reducere viral belastning i blod og lymfoide væv og fækalt afgivelse forårsaget af infektion med pcv2. til aktiv immunisering af svin over 3 uger mod mycoplasma hyopneumoniae for at reducere lungelæsioner forårsaget af infektion med m. hyopneumoniae.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiske stoffer til suidae - svin (slagtekyllinger) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - mycoplasma synoviae, stamme ms1, levende, svækket - lyofilisat til okulonasal suspension - fjerkræ

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merial norden a/s - mycoplasma hyopneumonia, stamme bq 14 (inaktiveret) - injektionsvæske, suspension - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - mycoplasma hyopneumoniae, inaktiveret - injektionsvæske, emulsion - 5,5 elisa enheder/ml - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

salfarm danmark a/s - mycoplasma hyopneumoniae, stamme atcc 25095, antigen (inaktiveret) - injektionsvæske, suspension - min 1,0 elisa enh/ml - svin